Frontierby eninvs

Language: EN · RU

← Region

Ozon Pharm USD

Update

Re-runs extraction for each period with period-end year from max(2023, current year − 2) through the current year, oldest first (up to three reporting years). This can take a long time.

Sector: Healthcare

RU_OZPH

Price chart

46.05 RUBDay -0.26%

Key metrics

Net debt (table and EV/EBITDA): |short-term borrowings| + |long-term borrowings| + |other financial liabilities| when extracted + |non-controlling interest| when extracted − |cash and equivalents|; amounts in millions of the reporting currency.

Market

Price
46.05 RUB · -0.26%
Market cap
754 mln USD

Growth

Δ revenue y/y
15.4%
Δ EBITDA y/y
16.4%

Multiples

P/E (LTM)
8.7x
3y avg: 10.1x
P/B (FY)
1.6x
P/E (ann.)
4.9x
EV/EBITDA (LTM)
59.8x
3y avg: 72.8x
EV/EBITDA (ann.)
41.9x

Cash return

Dividend yield
2.3%
FCF yield (LTM)
116.6%

Liquidity

Daily turnover (MOEX)
85.5 mln RUB

Shares: connector/market_inputs

Amounts: USD (converted) · As reported
Converted modes use NBK / ECB-linked rates: balance sheet date for BS items, period average for P&L and cash flow (see filing row evidence). As reported keeps each row in its filing currency.

🔍 Sanity check — subtotal consistency (Level-1 + Level-2) OK: 8 / Warn: 5 / Err: 4 / Autofix applied: 0
Port of PHP subtotal-total + sign-flip detection logic
PeriodIssues
2023-06-30 Q2OK
2023-09-30 9MOK
2023-09-30 Q3Warn 1
2023-12-31 FYOK
2023-12-31 Q4Errors 1
2024-03-31 Q1Errors 1Warn 2
2024-06-30 Q2Warn 1
2024-09-30 9MWarn 2
2024-09-30 Q3Errors 1Warn 2
2024-12-31 FYOK
2024-12-31 Q4Warn 1
2025-03-31 Q1OK
2025-06-30 Q2Errors 1Warn 2
2025-09-30 9MOK
2025-09-30 Q3OK
2025-12-31 FYOK
2025-12-31 Q4Warn 2
All checks pass · Has warnings (review) · Has errors (needs fix) · ✓* Autofix applied (see evidence)

Financial dynamics

Monetary columns are in M USD, one decimal; scale (K/M/B/T) keeps values readable. For the period (default) shows P&L and cash flow for that row’s reporting window: quarterly amounts when the feed uses quarter-duration facts (typical US 10-Q revenue and income), quarterly cash flows after stripping YTD where only cumulative tags exist, and an implied Q4 on 31 Dec FY rows (P&L: FY minus Q1–Q3; operating / investing cash flow: FY 12m minus 9M YTD to 30 Sep when sourced from SEC builder evidence) so they match 10-Q scale. Some issuers still use cumulative YTD minus the prior row in the same calendar year. As reported shows values stored on each row (e.g. full-year on FY). Balance sheet is always as reported. Source JSON may use millions etc.; conversion uses amounts_unit per row.

DatePeriodStatusRevenueM USDOperating profitM USDD&AM USDEBITDAM USDNet profitM USDOperating CFM USDCapex + M&AM USDAssetsM USDEquityM USDROE (annualized)Net debtM USDSource
2025-12-31FY 2025 (12M)OK142.4
y/y 15.4%
55.4
y/y 16.8%
4.3
y/y 6.8%
59.7
y/y 16.0%
38.2
y/y 17.9%
-0.8746.6
y/y 7.5%
465.6
y/y 31.0%
19.3%9288.5
2025-09-30Q3 2025 (3M)PARTIAL114.6
y/y 52.7%
40.4
y/y 138.3%
4.4
y/y 0.0%
44.8
y/y 110.0%
24.3
y/y 356.3%
7.7720.0
y/y 25.8%
430.2
y/y 33.7%
7.7%17214.0
2025-06-30Q2 2025 (3M)OK89.9
y/y -4.2%
24.4
y/y -15.1%
4.5
y/y 19.8%
28.9
y/y -11.1%
10.1
y/y -37.2%
32.8-33.9706.1
y/y 31.0%
408.2
y/y 30.0%
10.4%7296.4
2025-03-31Q1 2025 (3M)PARTIAL96.1
y/y 45.2%
31.0
y/y 70.0%
3.6
y/y 0.0%
34.6
y/y 58.4%
13.9
y/y 28.0%
5.9696.1
y/y
369.3
y/y
15.4%18997.0
2024-12-31FY 2024 (12M)OK123.4
y/y
47.5
y/y
4.1
y/y
51.5
y/y
32.4
y/y
-5.6-18.9694.8
y/y 45.2%
355.3
y/y 48.0%
19.1%10167.4
2024-09-30Q3 2024 (3M)OK75.0
y/y -8.5%
17.0
y/y -53.1%
4.4
y/y 1404.3%
21.3
y/y -41.5%
5.3
y/y -80.4%
-11.7-18.9572.1
y/y
321.7
y/y
2.2%10097.0
2024-06-30Q2 2024 (3M)OK93.9
y/y 73.1%
28.7
y/y 186.5%
3.8
y/y 19.4%
32.5
y/y 146.6%
16.0
y/y 253.1%
66.2-9.4539.1
y/y
313.9
y/y
8209.8
2024-03-31Q1 2024 (3M)PARTIAL66.2
y/y
18.2
y/y
3.6
y/y
21.8
y/y
10.9
y/y
32.8-9.4
y/y
y/y
10006.0
2023-12-31FY 2023 (12M)OK
y/y
y/y
y/y
y/y
y/y
478.5
y/y
240.1
y/y
13478.1
2023-09-30Q3 2023 (3M)PARTIAL82.0
y/y
36.2
y/y
0.3
y/y
36.5
y/y
27.1
y/y
22.6-3.6
y/y
y/y
9058.0
2023-06-30Q2 2023 (3M)PARTIAL54.2
y/y
10.0
y/y
3.2
y/y
13.2
y/y
4.5
y/y
28.9-6.0
y/y
y/y
9458.0
Data quality — review suggested

Revenue & EBITDA

RevenueEBITDA

Quarterly values ($ mln)

-500501001502002023 q32023 q42024 q12024 q22024 q32024 q42025 q12025 q22025 q32025 q4

Year-over-year change

-200%-100%0%100%2023 q32023 q42024 q12024 q22024 q32024 q42025 q12025 q22025 q32025 q4

Cash flow

Net debt / cash ($ mln)

05 00010 00015 00020 0002023 q32023 q42024 q12024 q22024 q32024 q42025 q12025 q22025 q32025 q4

Fundamental value creation

Value the company creates per year, as a % of market cap

Value created per year: +173.8%

How this was calculated
1. EBITDA growth (latest quarter YoY, annualised)
[EBITDA latest qtr − EBITDA year-ago qtr] × annualisation X (2025-12-31 vs 2024-12-31)
= (60 − 51) × 2.81
24
2. Current EV/EBITDA (LTM)
(Market cap + Net debt) ÷ EBITDA (LTM)
= (754 + 9 288) ÷ 168
30.0x — capped at 30x
3. Target multiple
(Current EV/EBITDA + 6.5) ÷ 2
= (30.0 + 6.5) ÷ 2
18.2x
4. Cash flow (balance method, LTM)
Net-debt reduction + dividends + buybacks − equity issuance
= 879 + 0 + 0 − 0
879
5. Value created per year
(EBITDA growth × Target multiple + Cash flow) ÷ Market cap
= (24 × 18.2 + 879) ÷ 754
+173.8%

Amounts in millions of the reporting currency. EBITDA growth is the latest quarter vs the same quarter a year ago, annualised.

Caveats:

Dividends

No dividend rows found for this issuer.

Reporting forms detected in loaded periods: (Balance sheet / Profit or loss (P&L) / Cash flows)